Literature DB >> 35261790

Significant association between serum Wisteria floribunda agglutinin-positive Mac-2-binding protein and prognosis of hepatocellular carcinoma after surgical treatment.

Ming-Tsung Lin1,2, Sherry Yueh-Hsia Chiu1,3, Kuo-Chin Chang1, Wei-Feng Li4, Chee-Chien Yong4, Yueh-Wei Liu4, Jing-Houng Wang1, Fang-Ying Kuo5, Chao-Cheng Huang5, Chih-Chi Wang4, Chang-Chun Hsiao2,6, Tsung-Hui Hu1.   

Abstract

Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) is a novel marker for evaluating fibrosis and predicting the development of hepatocellular carcinoma (HCC). However, the role of WFA+-M2BP in the prognosis of HCC patients after curative surgery remains unknown. In this study, we aimed to evaluate the prognostic role of serum WFA+-M2BP in HCC patients after curative resection and liver transplantation. We enrolled 460 HCC patients (357 resection and 103 transplantation) to analyze the risk factors for HCC recurrence and patient's survival. We employed time-to-event models using univariate and multivariable Cox proportional hazards regression analyses and calculated the hazard ratios (HRs) and adjusted HRs with their corresponding 95% confidence intervals (CIs). The levels of WFA+-M2BP were 0.19-14.51 COI (median 1.08) in patients of hepatectomy and 0.47-19.90 COI (median 6.0) in transplant patients. The levels of WFA+-M2BP in liver transplant patients is much higher than that of hepatectomy patients. Overall, liver fibrotic stage was positively correlated to WFA+-M2BP levels (P<0.0001). This study demonstrated that elevated WFA+-M2BP level (COI ≥0.75) was associated with a higher HCC recurrence rate in the resection group (P<0.001). Survival analysis showed that an elevated WFA+-M2BP level (COI ≥1.43) is associated with a higher mortality risk after surgical resection (P=0.0088) in the univariate analysis only. In liver transplant patients, WFA+-M2BP level (COI ≥3.81) did not predict HCC recurrence at all, but was associated poor survival after transplantation, with a borderline significance (P=0.0943). Serum WFA+-M2BP is a reliable marker for liver fibrosis in the present study. It is also reliable marker to predict prognosis of HCC after surgical resection. However, the prognostic role of WFA+-M2BP in HCC related transplants is equivocal, which is different from that of surgical resection. AJCR
Copyright © 2022.

Entities:  

Keywords:  Hepatocellular carcinoma; WFA+-M2BP; hepatitis B; hepatitis C; liver fibrosis

Year:  2022        PMID: 35261790      PMCID: PMC8899980     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  44 in total

1.  Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma.

Authors:  Shu-Yein Ho; Chia-Yang Hsu; Po-Hong Liu; Cheng-Yuan Hsia; Chien-Wei Su; Yi-Hsiang Huang; Ming-Chih Hou; Teh-Ia Huo
Journal:  Eur J Surg Oncol       Date:  2018-11-01       Impact factor: 4.424

2.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

3.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection.

Authors:  Arie Regev; Mariana Berho; Lennox J Jeffers; Clara Milikowski; Enrique G Molina; Nikolaos T Pyrsopoulos; Zheng-Zhou Feng; K Rajender Reddy; Eugene R Schiff
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

4.  Diagnostic sensitivity of hepatocellular carcinoma imaging and its application to non-cirrhotic patients.

Authors:  Ming-Tzung Lin; Chao-Long Chen; Chih-Chi Wang; Yu-Fan Cheng; Hock-Liew Eng; Jing-Houng Wang; King-Wah Chiu; Chuan-Mo Lee; Tsung-Hui Hu
Journal:  J Gastroenterol Hepatol       Date:  2011-04       Impact factor: 4.029

Review 5.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

6.  Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.

Authors:  Yu-Yun Shao; Shen-Yung Wang; Shi-Ming Lin
Journal:  J Formos Med Assoc       Date:  2020-11-14       Impact factor: 3.282

7.  Utility of Mac-2 Binding Protein Glycosylation Isomer to Evaluate Graft Status After Liver Transplantation.

Authors:  Yusuke Kimura; Kojiro Taura; Nguyen Hai Nam; Yusuke Uemoto; Kenji Yoshino; Yoshinobu Ikeno; Yukihiro Okuda; Takahiro Nishio; Gen Yamamoto; Kazutaka Tanabe; Yukinori Koyama; Takayuki Anazawa; Ken Fukumitsu; Takashi Ito; Shintaro Yagi; Naoko Kamo; Satoru Seo; Keiko Iwaisako; Koichiro Hata; Takumi Imai; Shinji Uemoto
Journal:  Liver Transpl       Date:  2020-10-01       Impact factor: 5.799

Review 8.  Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-11-29       Impact factor: 11.740

9.  A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.

Authors:  Atsushi Kuno; Yuzuru Ikehara; Yasuhito Tanaka; Kiyoaki Ito; Atsushi Matsuda; Satoru Sekiya; Shuhei Hige; Michiie Sakamoto; Masayoshi Kage; Masashi Mizokami; Hisashi Narimatsu
Journal:  Sci Rep       Date:  2013-01-15       Impact factor: 4.379

Review 10.  Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer.

Authors:  Joanne Marie O'Rourke; Vandana Mridhu Sagar; Tahir Shah; Shishir Shetty
Journal:  World J Gastroenterol       Date:  2018-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.